Phage products company Micreos revealed on Tuesday that it has received FDA & USDA approval for Phageguard-E as a 'GRAS' (Generally Recognized as Safe) food processing aid against E.coli O157.
Based in the Netherlands, the company's new PhageGuard-E product consists of natural phages against E.coli and the product is produced in Europe.
In conjunction with the US FDA approval, PhageGuard-E, a new surface intervention to combat E. coli O157 on food products, will now be available for the US beef industry. Micreos, a pioneer in targeted pathogen reduction technology, plans to start industrial scale projects with US meat processing companies shortly.
The company said the recent research conducted at the University of Neveda demonstrated superior results of PhageGuard-E surface spray on E. coli O157 contaminated fresh cold beef over currently used chemicals. The findings are of particular interest to beef processors looking for natural and effective post harvest interventions, reducing E. coli O157 on beef carcasses, primals, subs and trimmings.
Unlike harsh chemical interventions, phages are harmless to plant workers and do not damage equipment, concrete floors and water-treatment installations. Unlike traditional chemical treatments, PhageGuard-E kills E. coli without affecting the organoleptic properties of treated food products, concluded the company.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval